Angiotensin Receptor Antagonists
"Angiotensin Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that antagonize ANGIOTENSIN RECEPTORS. Many drugs in this class specifically target the ANGIOTENSIN TYPE 1 RECEPTOR.
| Descriptor ID |
D057911
|
| MeSH Number(s) |
D27.505.519.162
|
| Concept/Terms |
Angiotensin Receptor Antagonists- Angiotensin Receptor Antagonists
- Antagonists, Angiotensin Receptor
- Receptor Antagonists, Angiotensin
- Angiotensin Receptor Blockers
- Receptor Blockers, Angiotensin
|
Below are MeSH descriptors whose meaning is more general than "Angiotensin Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Angiotensin Receptor Antagonists".
This graph shows the total number of publications written about "Angiotensin Receptor Antagonists" by people in this website by year, and whether "Angiotensin Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 2 | 0 | 2 |
| 2015 | 1 | 2 | 3 |
| 2016 | 4 | 1 | 5 |
| 2017 | 21 | 31 | 52 |
| 2018 | 31 | 26 | 57 |
| 2019 | 16 | 12 | 28 |
| 2020 | 96 | 42 | 138 |
| 2021 | 39 | 28 | 67 |
| 2022 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Angiotensin Receptor Antagonists" by people in Profiles.
-
Serum potassium changes due to concomitant ACEI/ARB and spironolactone therapy: A systematic review and meta-analysis. Am J Health Syst Pharm. 2021 Dec 09; 78(24):2245-2255.
-
In-hospital use of ACE inhibitors/angiotensin receptor blockers associates with COVID-19 outcomes in African American patients. J Clin Invest. 2021 10 01; 131(19).
-
Angiotensin-converting enzyme 2 decreased expression during kidney inflammatory diseases: implications to predisposing to COVID-19 kidney complications. Kidney Int. 2021 11; 100(5):1138-1140.
-
Protocol for the Controlled evaLuation of Angiotensin Receptor blockers for COVID-19 respIraTorY disease (CLARITY): a randomised controlled trial. Trials. 2021 Aug 28; 22(1):573.
-
Renin-angiotensin system modulators in COVID-19 patients with hypertension: friend or foe? Clin Exp Hypertens. 2022 Jan 02; 44(1):1-10.
-
COVID-19 and the impact of arterial hypertension-An analysis of the international HOPE COVID-19 Registry (Italy-Spain-Germany). Eur J Clin Invest. 2021 Nov; 51(11):e13582.
-
Sex Differences in Association Between Anti-Hypertensive Medications and Risk of COVID-19 in Middle-Aged and Older Adults. Drugs Aging. 2021 10; 38(10):921-930.
-
Effect of ACE inhibitors and angiotensin receptor blockers on in-hospital mortality and length of stay in hospitalized COVID-19 patients. Vascul Pharmacol. 2021 12; 141:106902.
-
Comparison of Medication Prescribing Before and After the COVID-19 Pandemic Among Nursing Home Residents in Ontario, Canada. JAMA Netw Open. 2021 08 02; 4(8):e2118441.
-
Relationship between angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and COVID-19 incidence or severe disease. J Hypertens. 2021 08 01; 39(8):1717-1724.